All News EQL Pharma AB

Equities

EQL

SE0005497732

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
43.8 ^SEK	-0.23%		-0.90%	+31.14%

Apr. 22	EQL Pharma AB Announces Mellozzan Launched in Germany and Austria	CI
Feb. 13	EQL Pharma AB Provides Sales Guidance for the Year 2023/24	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EQL Pharma: Expecting strong growth amid margin challenges– Q4 preview	May. 10	AQ
Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2023/24	Apr. 29	AQ
Mellozzan[® ](melatonin) launched in Germany and Austria	Apr. 22	AQ
EQL Pharma AB Announces Mellozzan Launched in Germany and Austria	Apr. 22	CI
Mellozzan[® ](melatonin) have gained marketing approval in the UK	Mar. 14	AQ
Nomination committee for the 2024 Annual General Meeting	Feb. 16	AQ
EQL Pharma: Q3 numbers supportive of inflection point	Feb. 14	AQ
Interim Report April - December 2023	Feb. 13	AQ
EQL Pharma AB Provides Sales Guidance for the Year 2023/24	Feb. 13	CI
EQL Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 13	CI
Invitation to presentation in connection with EQL Pharma's quarterly report, third quarter, 2023/24	Jan. 30	AQ
EQL Pharma: Growth and margin inflection point – Q3(23/24) preview	Jan. 24	AQ
EQL Pharma: A repeat prescription for growth	Nov. 23	AQ
EQL Pharma again appointed Gazelle company in Skåne by Dagens Industri and once again places itself in 6th place out of 98 Skåne Gazelles	Nov. 20	AQ
Interim Report April - September 2023	Nov. 17	AQ
EQL Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 17	CI
Invitation to presentation in connection with EQL Pharma's quarterly report, second quarter, 2023/24	Nov. 06	AQ
EQL Pharma Plans 2024 Launch of Melatonin Product in Germany, Austria After Marketing Approvals	23-10-06	MT
Mellozzan[® ](melatonin) have gained marketing approval in Germany and Austria	23-10-06	AQ
EQL Pharma AB Announces its Mellozzan Gains Marketing Approval by Health Authorities in Germany and Austria	23-10-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News EQL Pharma AB

Equities

EQL

SE0005497732

All News

Filters